MA33939B1 - 5-alcynyl-pyrimidines - Google Patents
5-alcynyl-pyrimidinesInfo
- Publication number
- MA33939B1 MA33939B1 MA35083A MA35083A MA33939B1 MA 33939 B1 MA33939 B1 MA 33939B1 MA 35083 A MA35083 A MA 35083A MA 35083 A MA35083 A MA 35083A MA 33939 B1 MA33939 B1 MA 33939B1
- Authority
- MA
- Morocco
- Prior art keywords
- pyrimidine
- alkynyl
- drug
- excessive
- preparation
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/26—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
Abstract
La présente invention englobe des composés de formule générale (1), r1 à r3 étant définis comme dans la revendication 1, convenant au traitement de maladies caractérisées par une prolifération cellulaire excessive ou anormale, et leur utilisation pour préparer un médicament ayant les propriétés ci-dessus mentionnées.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP10151723 | 2010-01-26 | ||
PCT/EP2011/051061 WO2011092198A1 (fr) | 2010-01-26 | 2011-01-26 | 5-alcynyl-pyrimidines |
Publications (1)
Publication Number | Publication Date |
---|---|
MA33939B1 true MA33939B1 (fr) | 2013-01-02 |
Family
ID=42224366
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA35083A MA33939B1 (fr) | 2010-01-26 | 2011-01-26 | 5-alcynyl-pyrimidines |
Country Status (39)
Country | Link |
---|---|
US (3) | US8633183B2 (fr) |
EP (1) | EP2528903B1 (fr) |
JP (1) | JP5746219B2 (fr) |
KR (1) | KR101730933B1 (fr) |
CN (1) | CN102781923B (fr) |
AP (1) | AP3107A (fr) |
AR (1) | AR080020A1 (fr) |
AU (1) | AU2011209344B2 (fr) |
BR (1) | BR112012019437A2 (fr) |
CA (1) | CA2787407C (fr) |
CL (1) | CL2012001821A1 (fr) |
CO (1) | CO6640285A2 (fr) |
CY (1) | CY1118129T1 (fr) |
DK (1) | DK2528903T3 (fr) |
EA (1) | EA027501B1 (fr) |
ES (1) | ES2598230T3 (fr) |
GE (1) | GEP20156229B (fr) |
HK (1) | HK1175175A1 (fr) |
HR (1) | HRP20161308T1 (fr) |
HU (1) | HUE030721T2 (fr) |
IL (1) | IL220674A (fr) |
IN (1) | IN2012DN06602A (fr) |
LT (1) | LT2528903T (fr) |
MA (1) | MA33939B1 (fr) |
ME (1) | ME02511B (fr) |
MX (1) | MX2012008128A (fr) |
MY (1) | MY160241A (fr) |
NZ (1) | NZ601121A (fr) |
PE (1) | PE20121695A1 (fr) |
PL (1) | PL2528903T3 (fr) |
PT (1) | PT2528903T (fr) |
RS (1) | RS55265B1 (fr) |
SG (1) | SG182675A1 (fr) |
SI (1) | SI2528903T1 (fr) |
TN (1) | TN2012000369A1 (fr) |
TW (1) | TWI596093B (fr) |
UA (1) | UA110471C2 (fr) |
UY (1) | UY33199A (fr) |
WO (1) | WO2011092198A1 (fr) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5599791B2 (ja) | 2008-07-29 | 2014-10-01 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 5−アルキニル−ピリミジン |
CN104945420A (zh) | 2009-06-29 | 2015-09-30 | 因塞特公司 | 作为pi3k抑制剂的嘧啶酮类 |
WO2011075643A1 (fr) | 2009-12-18 | 2011-06-23 | Incyte Corporation | Dérivés condensés d'hétéroaryles substitués à titre d'inhibiteurs de pi3k |
US8680108B2 (en) | 2009-12-18 | 2014-03-25 | Incyte Corporation | Substituted fused aryl and heteroaryl derivatives as PI3K inhibitors |
US8618111B2 (en) * | 2010-01-26 | 2013-12-31 | Boehringer Ingelheim International Gmbh | 5-alkynyl-pyrimidines |
UY33199A (es) | 2010-01-26 | 2011-08-31 | Boehringer Ingelheim Int | 5-alquinil-pirimidinas. |
WO2011130342A1 (fr) | 2010-04-14 | 2011-10-20 | Incyte Corporation | Dérivés condensés en tant qu'inhibiteurs de ρi3κδ |
HUE028983T2 (en) | 2010-05-06 | 2017-01-30 | Vertex Pharma | Heterocyclic chromene-spirocyclic piperidine amides as ion channel modulators |
US9062055B2 (en) | 2010-06-21 | 2015-06-23 | Incyte Corporation | Fused pyrrole derivatives as PI3K inhibitors |
WO2012087881A1 (fr) | 2010-12-20 | 2012-06-28 | Incyte Corporation | N-(1-(phényl substitué)éthyl)-9h-purin-6-amines en tant qu'inhibiteurs de pi3k |
US8466162B2 (en) * | 2011-01-26 | 2013-06-18 | Boehringer Ingelheim International Gmbh | 5-alkynyl-pyridines |
WO2012106499A1 (fr) | 2011-02-02 | 2012-08-09 | Vertex Pharmaceuticals Incorporated | Amides de pipéridine spirocyclique-pyrrolopyrazine en tant que modulateurs de canaux ioniques |
US10385070B2 (en) | 2011-02-18 | 2019-08-20 | Vertex Pharmaceuticals Incorporated | Chroman-spirocyclic piperidine amides as modulators of ion channels |
US9108984B2 (en) | 2011-03-14 | 2015-08-18 | Incyte Corporation | Substituted diamino-pyrimidine and diamino-pyridine derivatives as PI3K inhibitors |
WO2012125613A1 (fr) * | 2011-03-14 | 2012-09-20 | Vertex Pharmaceuticals Incorporated | Amides de pipéridine spirocycliques morpholines utilisés en tant que modulateurs de canaux ioniques |
WO2012135009A1 (fr) * | 2011-03-25 | 2012-10-04 | Incyte Corporation | Dérivés de pyrimidine-4,6-diamine en tant qu'inhibiteurs de pi3k |
PE20181272A1 (es) | 2011-09-02 | 2018-08-03 | Incyte Holdings Corp | Heterociclilaminas como inhibidores de pi3k |
AR090548A1 (es) | 2012-04-02 | 2014-11-19 | Incyte Corp | Azaheterociclobencilaminas biciclicas como inhibidores de pi3k |
AR092211A1 (es) * | 2012-09-24 | 2015-04-08 | Merck Patent Ges Mit Beschränkter Haftung | Derivados de hidropirrolopirrol |
CA2934251C (fr) | 2013-12-20 | 2024-01-02 | 3-V Biosciences, Inc. | Combinaison de modulateurs heterocycliques de synthese des lipides et medicaments chimiotherapeutiques dans le traitement du cancer |
US10077277B2 (en) | 2014-06-11 | 2018-09-18 | Incyte Corporation | Bicyclic heteroarylaminoalkyl phenyl derivatives as PI3K inhibitors |
ES2838573T3 (es) | 2014-08-21 | 2021-07-02 | Bristol Myers Squibb Co | Derivados de benzamida ligados como inhibidores potentes de ROCK |
RS63963B1 (sr) | 2015-02-27 | 2023-03-31 | Incyte Holdings Corp | Postupak pripreme pi3k inhibitora |
CN104803921A (zh) * | 2015-03-14 | 2015-07-29 | 长沙深橙生物科技有限公司 | 一种苯取代嘧啶衍生物的制备方法 |
CN104803922A (zh) * | 2015-03-14 | 2015-07-29 | 长沙深橙生物科技有限公司 | 一种嘧啶衍生物的制备方法 |
CN104744376A (zh) * | 2015-03-14 | 2015-07-01 | 长沙深橙生物科技有限公司 | 一种2-异丙基嘧啶衍生物的制备方法 |
US9732097B2 (en) | 2015-05-11 | 2017-08-15 | Incyte Corporation | Process for the synthesis of a phosphoinositide 3-kinase inhibitor |
WO2016183063A1 (fr) | 2015-05-11 | 2016-11-17 | Incyte Corporation | Formes cristallines d'un inhibiteur de pi3k |
BR112023015210A2 (pt) * | 2021-01-29 | 2023-11-07 | Cedilla Therapeutics Inc | Inibidores de cdk2 e métodos de uso dos mesmos |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3832570A1 (de) | 1988-09-24 | 1990-03-29 | Hoechst Ag | 7-substituierte derivate der 3,5-dihydroxyhept-6-insaeure, verfahren zur ihrer herstellung, ihre verwendung als arzneimittel, sowie zwischenprodukte |
EP0674627A1 (fr) | 1992-12-18 | 1995-10-04 | The Wellcome Foundation Limited | Derives de pyrimidine, de pyridine, de pteridinone et d'indazole utilises comme inhibiteurs enzymatiques |
US5622954A (en) | 1994-05-11 | 1997-04-22 | Fmc Corporation | 5[W(substituted aryl)alkenylene and alkynylene]-2,4-diaminopyrimidines as pesticides |
CA2398274C (fr) | 2000-02-25 | 2009-09-22 | F. Hoffmann-La Roche Ag | Modulateurs de recepteurs de l'adenosine |
ATE469132T1 (de) | 2000-07-24 | 2010-06-15 | Krenitsky Pharmaceuticals Inc | Substituierte 5-alkinyl-pyrimidine mit neurotropher wirkung |
CN100430389C (zh) * | 2002-08-16 | 2008-11-05 | 阿斯利康(瑞典)有限公司 | 抑制磷酸肌醇3-激酶β |
JP2007502298A (ja) * | 2003-08-14 | 2007-02-08 | スミスクライン ビーチャム コーポレーション | 化合物 |
ATE402705T1 (de) | 2003-12-24 | 2008-08-15 | Astrazeneca Ab | Pyrimidine mit tie2 (tek) aktivität |
JP2006044823A (ja) * | 2004-07-30 | 2006-02-16 | Hitachi Building Systems Co Ltd | 乗客コンベアのハンドレール案内装置 |
AU2005293556A1 (en) * | 2004-10-12 | 2006-04-20 | Merck Serono Sa | PI3 Kinase gamma inhibitors for the treatment of anaemia |
US7776869B2 (en) | 2004-10-18 | 2010-08-17 | Amgen Inc. | Heteroaryl-substituted alkyne compounds and method of use |
JP2008528663A (ja) | 2005-02-01 | 2008-07-31 | アストラゼネカ アクチボラグ | Ties(TEK)阻害活性を有するピリミジン化合物 |
US20080146599A1 (en) | 2005-02-01 | 2008-06-19 | Astrazeneca Ab | Pyrimidine Compounds Having Tie-2 (Tek) Inhibitory Activity |
US20070135437A1 (en) | 2005-03-04 | 2007-06-14 | Alsgen, Inc. | Modulation of neurodegenerative diseases |
WO2006106721A1 (fr) | 2005-03-30 | 2006-10-12 | Shionogi & Co., Ltd. | Dérivé de pyrimidine ayant un effet d'inhibition de la tyrosine kinase |
GB0506467D0 (en) * | 2005-03-31 | 2005-05-04 | Astrazeneca Ab | Compounds |
US20080194552A1 (en) * | 2005-03-31 | 2008-08-14 | Astrazeneca Ab | Aminopyrimidine Derivatives With Tie2 Inhibiting Activity |
AR060632A1 (es) * | 2006-04-26 | 2008-07-02 | Genentech Inc | Compuestos inhibidores de fosfoinositida 3- quinasa y metodos de uso |
WO2008023180A1 (fr) | 2006-08-24 | 2008-02-28 | Astrazeneca Ab | Dérivés de morpholino pyrimidine utiles dans le traitement de désordres prolifératifs |
JP5283633B2 (ja) | 2006-12-29 | 2013-09-04 | テイボテク・フアーマシユーチカルズ | Hiv阻害性5,6−置換ピリミジン |
EP2022785A1 (fr) | 2007-06-20 | 2009-02-11 | Bayer Schering Pharma Aktiengesellschaft | Alkynylpyrimidines comme inhibiteurs de la kinase Tie2 |
JP5599791B2 (ja) * | 2008-07-29 | 2014-10-01 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 5−アルキニル−ピリミジン |
UY33199A (es) | 2010-01-26 | 2011-08-31 | Boehringer Ingelheim Int | 5-alquinil-pirimidinas. |
US8618111B2 (en) * | 2010-01-26 | 2013-12-31 | Boehringer Ingelheim International Gmbh | 5-alkynyl-pyrimidines |
-
2011
- 2011-01-24 UY UY0001033199A patent/UY33199A/es not_active Application Discontinuation
- 2011-01-24 US US13/012,082 patent/US8633183B2/en active Active
- 2011-01-25 TW TW100102688A patent/TWI596093B/zh not_active IP Right Cessation
- 2011-01-25 AR ARP110100241A patent/AR080020A1/es active IP Right Grant
- 2011-01-26 GE GEAP201112848A patent/GEP20156229B/en unknown
- 2011-01-26 EA EA201201030A patent/EA027501B1/ru not_active IP Right Cessation
- 2011-01-26 ME MEP-2016-223A patent/ME02511B/fr unknown
- 2011-01-26 IN IN6602DEN2012 patent/IN2012DN06602A/en unknown
- 2011-01-26 NZ NZ601121A patent/NZ601121A/en not_active IP Right Cessation
- 2011-01-26 CN CN201180011379.0A patent/CN102781923B/zh active Active
- 2011-01-26 PE PE2012001055A patent/PE20121695A1/es active IP Right Grant
- 2011-01-26 MA MA35083A patent/MA33939B1/fr unknown
- 2011-01-26 MX MX2012008128A patent/MX2012008128A/es active IP Right Grant
- 2011-01-26 PT PT117011304T patent/PT2528903T/pt unknown
- 2011-01-26 MY MYPI2012003354A patent/MY160241A/en unknown
- 2011-01-26 AU AU2011209344A patent/AU2011209344B2/en not_active Ceased
- 2011-01-26 CA CA2787407A patent/CA2787407C/fr not_active Expired - Fee Related
- 2011-01-26 JP JP2012550424A patent/JP5746219B2/ja active Active
- 2011-01-26 WO PCT/EP2011/051061 patent/WO2011092198A1/fr active Application Filing
- 2011-01-26 SG SG2012054367A patent/SG182675A1/en unknown
- 2011-01-26 LT LTEP11701130.4T patent/LT2528903T/lt unknown
- 2011-01-26 ES ES11701130.4T patent/ES2598230T3/es active Active
- 2011-01-26 UA UAA201209955A patent/UA110471C2/ru unknown
- 2011-01-26 PL PL11701130T patent/PL2528903T3/pl unknown
- 2011-01-26 RS RS20160871A patent/RS55265B1/sr unknown
- 2011-01-26 AP AP2012006360A patent/AP3107A/xx active
- 2011-01-26 SI SI201130989A patent/SI2528903T1/sl unknown
- 2011-01-26 KR KR1020127022277A patent/KR101730933B1/ko active IP Right Grant
- 2011-01-26 DK DK11701130.4T patent/DK2528903T3/en active
- 2011-01-26 EP EP11701130.4A patent/EP2528903B1/fr active Active
- 2011-01-26 HU HUE11701130A patent/HUE030721T2/en unknown
- 2011-01-26 BR BR112012019437A patent/BR112012019437A2/pt not_active Application Discontinuation
-
2012
- 2012-06-28 IL IL220674A patent/IL220674A/en active IP Right Grant
- 2012-07-04 CL CL2012001821A patent/CL2012001821A1/es unknown
- 2012-07-23 TN TNP2012000369A patent/TN2012000369A1/en unknown
- 2012-07-27 CO CO12126468A patent/CO6640285A2/es active IP Right Grant
-
2013
- 2013-02-26 HK HK13102374.7A patent/HK1175175A1/zh not_active IP Right Cessation
- 2013-11-22 US US14/087,179 patent/US9321771B2/en active Active
-
2016
- 2016-03-18 US US15/073,795 patent/US20160199383A1/en not_active Abandoned
- 2016-10-10 HR HRP20161308TT patent/HRP20161308T1/hr unknown
- 2016-10-19 CY CY20161101049T patent/CY1118129T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA33939B1 (fr) | 5-alcynyl-pyrimidines | |
MX2013004491A (es) | Boronatos como inhibidores de arginasa. | |
MA32811B1 (fr) | Nouveaux composés | |
IN2015DN01156A (fr) | ||
EA201201648A1 (ru) | Стимуляторы sgc | |
EA201490493A1 (ru) | Пирано[3,2-d][1,3]тиазол в качестве ингибиторов гликозидазы | |
EA201290980A1 (ru) | Производные 1-амино-2-циклопропилэтилбороновой кислоты | |
MA33937B1 (fr) | Composes pyrazole comme antagonistes du recepteur crth2 | |
MX2013000821A (es) | Nuevas aminopirazoloquinazolinas. | |
MX2014012695A (es) | Derivados de isoindolona. | |
UA109010C2 (en) | MORPHOLINOPYRIMIDINES AND THEIR APPLICATIONS IN THERAPY | |
MX341565B (es) | 3-amino-piridinas como agonistas de receptor de acido biliar acoplado a proteina g1 (gpbar1). | |
PH12014501967B1 (en) | Benzodioxanes in combination with other actives for inhibiting leukotriene production | |
MA32505B1 (fr) | 5-alcynyl-pyrimidines | |
MA35816B1 (fr) | Dérivés d'aniline, leur préparation et leur application thérapeutique | |
MY167898A (en) | Co-crystals and salts of ccr3-inhibitors | |
MX2010009837A (es) | Tiazolil-dihidro-indazoles. | |
TN2011000531A1 (en) | 5- alkynyl - pyridines | |
MX2014005538A (es) | 1-piridazinil-hidroxiimino-3-fenil-propanos como agonistas de proteina g-receptor acoplado a acido biliar 1 (gpbar1). | |
MX2013006670A (es) | Derivado de 2-carboxamida-4-piperazinil-benzofurano. | |
IN2012DN06600A (fr) | ||
EA201101537A1 (ru) | Тиатриазациклопентазулены в качестве ингибиторов pi3-киназ, предназначенные для лечения рака | |
MX2014004853A (es) | 1-cicloalquil- o 1-heterociclil-hidroxiimino-3-fenil-propanos. | |
CA2863110A1 (fr) | Derives de 1,2-pyridazine, 1,6-pyridazine ou pyrimidine-benzamide comme modulateurs de gpbar1 | |
TN2013000012A1 (en) | New aminopyrazoloquinazolines |